Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells

Interleukin-2 (IL-2) is a T-cell proliferating factor used for cancer immunotherapy. Here, the authors develop a long-lived variant of IL-2 that, mutated in its binding domain, drives a much more potent tumour regression by depleting CD25+ CD4+regulatory T-cells via targeting them for phagocytosis.

Guardado en:

Detalles Bibliográficos
Autores principales:	Rodrigo Vazquez-Lombardi, Claudia Loetsch, Daniela Zinkl, Jennifer Jackson, Peter Schofield, Elissa K. Deenick, Cecile King, Tri Giang Phan, Kylie E. Webster, Jonathan Sprent, Daniel Christ
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/5b8e946c736b4be78cfb86f8d067ec42
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5b8e946c736b4be78cfb86f8d067ec42
record_format	dspace
spelling	oai:doaj.org-article:5b8e946c736b4be78cfb86f8d067ec422021-12-02T15:38:46ZPotent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells10.1038/ncomms153732041-1723https://doaj.org/article/5b8e946c736b4be78cfb86f8d067ec422017-05-01T00:00:00Zhttps://doi.org/10.1038/ncomms15373https://doaj.org/toc/2041-1723Interleukin-2 (IL-2) is a T-cell proliferating factor used for cancer immunotherapy. Here, the authors develop a long-lived variant of IL-2 that, mutated in its binding domain, drives a much more potent tumour regression by depleting CD25+ CD4+regulatory T-cells via targeting them for phagocytosis.Rodrigo Vazquez-LombardiClaudia LoetschDaniela ZinklJennifer JacksonPeter SchofieldElissa K. DeenickCecile KingTri Giang PhanKylie E. WebsterJonathan SprentDaniel ChristNature PortfolioarticleScienceQENNature Communications, Vol 8, Iss 1, Pp 1-12 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Rodrigo Vazquez-Lombardi Claudia Loetsch Daniela Zinkl Jennifer Jackson Peter Schofield Elissa K. Deenick Cecile King Tri Giang Phan Kylie E. Webster Jonathan Sprent Daniel Christ Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
description	Interleukin-2 (IL-2) is a T-cell proliferating factor used for cancer immunotherapy. Here, the authors develop a long-lived variant of IL-2 that, mutated in its binding domain, drives a much more potent tumour regression by depleting CD25+ CD4+regulatory T-cells via targeting them for phagocytosis.
format	article
author	Rodrigo Vazquez-Lombardi Claudia Loetsch Daniela Zinkl Jennifer Jackson Peter Schofield Elissa K. Deenick Cecile King Tri Giang Phan Kylie E. Webster Jonathan Sprent Daniel Christ
author_facet	Rodrigo Vazquez-Lombardi Claudia Loetsch Daniela Zinkl Jennifer Jackson Peter Schofield Elissa K. Deenick Cecile King Tri Giang Phan Kylie E. Webster Jonathan Sprent Daniel Christ
author_sort	Rodrigo Vazquez-Lombardi
title	Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
title_short	Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
title_full	Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
title_fullStr	Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
title_full_unstemmed	Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells
title_sort	potent antitumour activity of interleukin-2-fc fusion proteins requires fc-mediated depletion of regulatory t-cells
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/5b8e946c736b4be78cfb86f8d067ec42
work_keys_str_mv	AT rodrigovazquezlombardi potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT claudialoetsch potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT danielazinkl potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT jenniferjackson potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT peterschofield potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT elissakdeenick potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT cecileking potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT trigiangphan potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT kylieewebster potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT jonathansprent potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells AT danielchrist potentantitumouractivityofinterleukin2fcfusionproteinsrequiresfcmediateddepletionofregulatorytcells
_version_	1718386111853625344

Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells

Ejemplares similares